文献速递心外重症与机械循环支持

持续流左心室辅助装置术前蛋白尿与临床结局的关系

Pre-operative proteinuria in left ventricular assist devices and clinical outcome.
PubMed 文献 · J Heart Lung Transplant · 2017-07-15

这项回顾性多中心队列研究纳入173例植入持续流左心室辅助装置(CF-LVAD)的患者,24%存在术前蛋白尿。术前蛋白尿患者3个月和1年生存率分别为57%和52%,显著低于无蛋白尿患者的86%和78%(log-rank p < 0.001)。多因素Cox回归证实术前蛋白尿是全因死亡和术后1年内需肾脏替代治疗(RRT)的独立预测因子。

要点

  • CF-LVAD术前蛋白尿发生率为24%,与1年生存率降低独立相关(校正HR 2.09)。
  • 术前蛋白尿患者术后1年需RRT比例更高(32% vs 15%,校正HR 2.23)。
  • 建议将术前蛋白尿纳入CF-LVAD候选者的风险分层评估。

核心结论

  • 术前蛋白尿是CF-LVAD患者全因死亡和术后1年内需RRT的独立预测因子,应纳入候选者风险分层。

研究设计与样本

  • 回顾性多中心队列研究,评估2个三级转诊中心共241例接受CF-LVAD植入的患者,最终纳入173例在术前7天内完成尿试纸检测者。

主要发现

  • 173例纳入患者中42例(24%)存在术前蛋白尿,78%为男性,平均年龄52.3 ± 13.3岁,平均eGFR 60.1 ± 25.9 mL/min/1.73 m2。
  • 蛋白尿组与非蛋白尿组3个月生存率分别为57%和86%,1年生存率分别为52%和78%(log-rank p < 0.001)。
  • 术后1年内蛋白尿组32%需RRT,非蛋白尿组15%需RRT(log-rank p = 0.02)。
  • 多因素Cox回归显示术前蛋白尿是全因死亡的独立预测因子(校正HR 2.09,95%CI 1.10-3.80,p = 0.02)。
  • 多因素Cox回归显示术前蛋白尿是术后1年内需RRT的独立预测因子(校正HR 2.23,95%CI 1.13-4.84,p = 0.02)。

关键数值与推荐

  • 蛋白尿定义为尿试纸检测trace或以上。
  • 纳入条件为CF-LVAD植入前7天内完成尿试纸检测。

临床怎么用

  • 在筛选CF-LVAD候选者时,应检测术前尿试纸蛋白尿以辅助风险分层。
  • 对存在术前蛋白尿的患者,应加强术后肾功能监测并预判RRT需求。

局限性

  • 研究为回顾性设计。
  • 仅纳入术前7天内完成尿试纸检测的患者(241例中173例),可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study evaluated the association of pre-operative proteinuria before continuous flow left ventricular assist device (CF-LVAD) implantation in relation to mortality and the need for renal replacement therapy (RRT) during the first year of follow-up. METHODS: This retrospective, multicenter cohort study evaluated all patients (n = 241) who underwent CF-LVAD implantation in the 2 participating tertiary referral centers. Patients were included if a urine dipstick was performed within 7 days before CF-LVAD implantation. Proteinuria was defined as trace or higher. RESULTS: In total, 173 patients (72%) were included (78% men; mean age, 52.3 ± 13.3; mean estimated glomerular filtration rate, 60.1 ± 25.9 mL/min/1.73 m2), and 42 patients (24%) had pre-operative proteinuria. The observed survival in patients with proteinuria vs without proteinuria was 57% vs 86% at 3 months and 52% vs 78% at 1 year (log-rank p < 0.001), respectively. In addition, during the first year after implantation, 32% of the patients with proteinuria and 15% of the patients without proteinuria required RRT (log-rank p = 0.02). Multivariate Cox regression analysis confirmed that pre-operative proteinuria was an independent predictor for mortality (adjusted hazard ratio, 2.09; 95% confidence interval, 1.10-3.80, p = 0.02) and for the need of RRT during the first year (adjusted hazard ratio, 2.23; 95% confidence interval, 1.13-4.84; p = 0.02). CONCLUSIONS: Proteinuria, which was present in 25% of all tested LVAD patients, predicts worse outcome in all-cause mortality and need of RRT in patients with a CF-LVAD. This warrants the use of proteinuria in risk stratification when selecting patients for CF-LVAD therapy.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Muslem R, Caliskan K, Akin S, et al. Pre-operative proteinuria in left ventricular assist devices and clinical outcome. J Heart Lung Transplant. 2017. PMID: 28781011. doi:10.1016/j.healun.2017.07.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。